Crizotinib is five times more effective at blocking ROS1 than ALK, according to the ROS1-specific structure, which explains why ROS1-positive NSCLC experienced greater responses than ALK-positive ones. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.